查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589461

糖尿病相关眼部治疗市场：按产品类型、应用和最终用途划分－2025-2030 年全球预测

Diabetes Associated Ophthalmic Treatment Market by Product Type (Devices, Drugs), Application (Cataract, Diabetic associated Macular Degeneration, Diabetic Macular Edema), End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，糖尿病相关眼科保健市场价值为57.1亿美元，预计2024年将达到61.8亿美元，复合年增长率为8.59%，预计到2030年将达到101.8亿美元。

与糖尿病相关的眼部护理包括用于管理和缓解糖尿病引起的眼部相关併发症（例如糖尿病视网膜病变和糖尿病黄斑部水肿）的医疗干预措施和产品。随着全球糖尿病盛行率的不断上升，导致相关眼科疾病的增加，这一领域至关重要。应用涵盖为糖尿病患者量身定制的诊断、治疗和监测技术。主要最终用户包括医院、诊所和眼科专科中心。推动该市场的主要成长要素包括糖尿病人口的增加、医疗技术的进步以及医疗保健支出的增加。成长机会包括人工智慧在诊断中的整合、新药物输送系统的开发以及成像技术的增强，为公司提供了重要的成长途径。对相关人员的建议包括投资于研发以创新具有更高功效和患者依从性的产品，利用策略伙伴关係进行技术整合，以及增加糖尿病患者的数量，其中包括扩展到新兴市场。

主要市场统计
基准年[2023] 57.1亿美元
预测年份 [2024] 61.8亿美元
预测年份 [2030] 101.8亿美元
复合年增长率（%） 8.59%

然而，市场限制包括先进治疗和技术的高成本可能会限制低收入者的使用，以及监管要求的复杂性导致产品上市延迟。新兴国家面临医疗基础设施不足的挑战，影响了市场渗透率。创新将针对具有成本效益的治疗解决方案、偏远和服务不足地区的携带式诊断设备以及个人化医疗。趋势表明，作为影响患者管理的数位健康方面，精准医疗和远距眼科的趋势不断增长。市场的本质是动态和竞争的，频繁的技术进步和策略联盟是产业成功的重要组成部分。公司保持适应性，专注于产品本地化以满足不同的监管和患者需求，透过环保实践确保永续性，并改善与糖尿病相关的眼部併发症的早期检测和管理，必须优先考虑患者的教育。

市场动态：快速发展的糖尿病相关眼科治疗市场的关键市场洞察

供需的动态交互作用正在改变与糖尿病相关的眼部保健市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 老年人口增加导致糖尿病盛行率增加
    • 人们越来越倾向早期诊断糖尿病
    • 提高与糖尿病眼疾相关的认识倡议
  • 市场限制因素
    • 缺乏熟练且知识渊博的眼科医生
  • 市场机会
    • 活性化研发活动以开发先进的糖尿病眼部治疗方法
    • 糖尿病相关眼部治疗设备的巨大潜力
  • 市场挑战
    • 糖尿病相关眼部治疗药物的核准期限

波特五力：驾驭糖尿病相关眼科治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解糖尿病相关眼科治疗市场的外部影响

外部宏观环境因素在塑造糖尿病相关眼部保健市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解糖尿病相关眼科治疗市场的竞争状况

对糖尿病相关眼科治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵糖尿病相关眼部治疗市场供应商的绩效评估

FPNV定位矩阵是评估糖尿病相关眼部保健市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为糖尿病相关眼部治疗市场的成功指明道路

对于旨在加强其在全球市场的影响力的公司来说，对糖尿病相关眼科治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 随着人口老化的加剧，糖尿病的发生率也随之增加
      • 糖尿病早期诊断的趋势日益增长
      • 加强提高人们对糖尿病眼疾的认识
    • 抑制因素
      • 缺乏熟练且知识渊博的眼科医生
    • 机会
      • 活性化旨在开发与糖尿病相关的先进眼科治疗方法的研发活动
      • 糖尿病相关眼部治疗设备的巨大潜力
    • 任务
      • 糖尿病相关眼部治疗药物核准週期长
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章糖尿病相关眼科治疗市场：依产品类型

  • 装置
  • 药品

第七章 糖尿病相关眼科治疗市场：依应用分类

  • 白内障
  • 糖尿病黄斑部病变
  • 糖尿病黄斑部水肿
  • 糖尿病视网膜病变
  • 干眼症
  • 眼睛过敏和感染疾病
  • 青光眼
  • 葡萄膜炎

第八章糖尿病相关眼科治疗市场：依最终用途分类

  • 门诊手术中心
  • 医院
  • 眼科中心

第九章北美及南美糖尿病相关眼部保健市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区糖尿病相关眼科治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲糖尿病相关眼科治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Adverum Biotechnologies, Inc.
  • Alimera Sciences, Inc.
  • Allergan PLC
  • Ampio Pharmaceuticals, Inc.
  • Apexian Pharmaceuticals, Inc.
  • Bausch & Lomb Incorporated.
  • Bayer AG
  • Eisai Co Ltd.
  • Graybug Vision Inc.
  • Kalvista Pharmaceuticals Ltd.
  • Kodiak Sciences Inc.
  • Kubota Vision Inc.
  • Novartis AG
  • Ocuphire Pharma, Inc.
  • Regeneron Pharmaceuticals Inc.
Product Code: MRR-563BF1FCF469

The Diabetes Associated Ophthalmic Treatment Market was valued at USD 5.71 billion in 2023, expected to reach USD 6.18 billion in 2024, and is projected to grow at a CAGR of 8.59%, to USD 10.18 billion by 2030.

The scope of diabetes-associated ophthalmic treatment encompasses a range of medical interventions and products designed to manage and mitigate eye-related complications stemming from diabetes, such as diabetic retinopathy and diabetic macular edema. This sector is crucial due to the increasing prevalence of diabetes globally, which leads to a rise in associated ocular disorders. The application extends across diagnostics, therapeutics, and monitoring technologies tailored for diabetic patients. The primary end-users include hospitals, clinics, and specialized ophthalmic centers. Key growth factors driving this market include the growing diabetic population, advancements in medical technology, and increased healthcare expenditure. Opportunities arise from the integration of AI in diagnostics, development of novel drug delivery systems, and enhanced imaging technologies, providing companies avenues for substantial growth. Recommendation for stakeholders involves investing in R&D to innovate products with better efficacy and patient compliance, leveraging strategic partnerships for technology integration, and expanding into emerging markets with growing diabetic incidences.

KEY MARKET STATISTICS
Base Year [2023] USD 5.71 billion
Estimated Year [2024] USD 6.18 billion
Forecast Year [2030] USD 10.18 billion
CAGR (%) 8.59%

However, market limitations include the high cost of advanced treatments and technologies, which may restrict access for lower-income groups, and the complexity of regulatory requirements that can delay product launches. Emerging economies face challenges with inadequate healthcare infrastructure, affecting market penetration. Innovation can be directed towards cost-effective treatment solutions, portable diagnostic devices for remote and underserved locations, and personalized medicine. Insights indicate an increasing trend towards precision medicine and teleophthalmology as facets of digital health influencing patient management. The nature of the market is dynamic and competitive, with frequent technological advancements and strategic collaborations forming an integral part of industry success. Businesses must remain adaptable, focusing on localization of products to meet diverse regulatory and patient needs, ensuring sustainability through eco-friendly practices, and prioritizing patient education on early detection and management of diabetes-related eye complications.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetes Associated Ophthalmic Treatment Market

The Diabetes Associated Ophthalmic Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of diabetes with rising geriatric population
    • Growing inclination towards early diagnosis of diabetes
    • Rising number of initiatives to increase awareness associated diabetes ophthalmic disease
  • Market Restraints
    • Lack of skilled and knowledgeable ophthalmologists
  • Market Opportunities
    • Rising R&D activities to develop advanced diabetes associated ophthalmic treatments
    • High potential for diabetes associated ophthalmic treatment devices
  • Market Challenges
    • Long duration of drug approvals for diabetes associated ophthalmic treatment

Porter's Five Forces: A Strategic Tool for Navigating the Diabetes Associated Ophthalmic Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetes Associated Ophthalmic Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetes Associated Ophthalmic Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetes Associated Ophthalmic Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetes Associated Ophthalmic Treatment Market

A detailed market share analysis in the Diabetes Associated Ophthalmic Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetes Associated Ophthalmic Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetes Associated Ophthalmic Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetes Associated Ophthalmic Treatment Market

A strategic analysis of the Diabetes Associated Ophthalmic Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetes Associated Ophthalmic Treatment Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Inc., Alimera Sciences, Inc., Allergan PLC, Ampio Pharmaceuticals, Inc., Apexian Pharmaceuticals, Inc., Bausch & Lomb Incorporated., Bayer AG, Eisai Co Ltd., Graybug Vision Inc., Kalvista Pharmaceuticals Ltd., Kodiak Sciences Inc., Kubota Vision Inc., Novartis AG, Ocuphire Pharma, Inc., and Regeneron Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Diabetes Associated Ophthalmic Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Devices and Drugs.
  • Based on Application, market is studied across Cataract, Diabetic associated Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Dry Eye Syndrome, Eye Allergy & Infection, Glaucoma, and Uveitis.
  • Based on End-use, market is studied across Ambulatory Surgical Centers, Hospitals, and Ophthalmic Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of diabetes with rising geriatric population
      • 5.1.1.2. Growing inclination towards early diagnosis of diabetes
      • 5.1.1.3. Rising number of initiatives to increase awareness associated diabetes ophthalmic disease
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of skilled and knowledgeable ophthalmologists
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising R&D activities to develop advanced diabetes associated ophthalmic treatments
      • 5.1.3.2. High potential for diabetes associated ophthalmic treatment devices
    • 5.1.4. Challenges
      • 5.1.4.1. Long duration of drug approvals for diabetes associated ophthalmic treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diabetes Associated Ophthalmic Treatment Market, by Product Type

  • 6.1. Introduction
  • 6.2. Devices
  • 6.3. Drugs

7. Diabetes Associated Ophthalmic Treatment Market, by Application

  • 7.1. Introduction
  • 7.2. Cataract
  • 7.3. Diabetic associated Macular Degeneration
  • 7.4. Diabetic Macular Edema
  • 7.5. Diabetic Retinopathy
  • 7.6. Dry Eye Syndrome
  • 7.7. Eye Allergy & Infection
  • 7.8. Glaucoma
  • 7.9. Uveitis

8. Diabetes Associated Ophthalmic Treatment Market, by End-use

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Ophthalmic Centers

9. Americas Diabetes Associated Ophthalmic Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Diabetes Associated Ophthalmic Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Diabetes Associated Ophthalmic Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adverum Biotechnologies, Inc.
  • 2. Alimera Sciences, Inc.
  • 3. Allergan PLC
  • 4. Ampio Pharmaceuticals, Inc.
  • 5. Apexian Pharmaceuticals, Inc.
  • 6. Bausch & Lomb Incorporated.
  • 7. Bayer AG
  • 8. Eisai Co Ltd.
  • 9. Graybug Vision Inc.
  • 10. Kalvista Pharmaceuticals Ltd.
  • 11. Kodiak Sciences Inc.
  • 12. Kubota Vision Inc.
  • 13. Novartis AG
  • 14. Ocuphire Pharma, Inc.
  • 15. Regeneron Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CATARACT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC ASSOCIATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRY EYE SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE ALLERGY & INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY UVEITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 150. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023